ELV:NYSE

Elevance Health (ELV) trades at $280.74, well below its DCF fair value of $334.27, implying roughly a 38% upside. The stock’s trailing P/E of 11.1 is almost half the industry average of 25.4, and a forward P/E of 9.5 signals earnings expansion. Revenue growth of 9.5% and a dividend yield of 2.38% with a modest 27% payout ratio suggest a sustainable income stream, reinforced by a strong cash position of $36.1 bn. However, the recent CMS freeze on Medicare Advantage enrollment introduces notable regulatory headwinds, and the company’s guidance for 2026 appears softer than prior expectations. Technical indicators show the stock is oversold (RSI 28) and near a support level of $274.84, while the MACD remains bearish, but volume is increasing, hinting at potential buying interest. The low beta (~0.22) underscores defensive behavior, yet 30‑day volatility exceeds 60%, reflecting short‑term price swings. Overall, the valuation gap, solid fundamentals, and defensive profile make ELV attractive, but investors should monitor regulatory developments and earnings guidance.
Given the blend of undervaluation, dividend sustainability, and defensive sector traits, a cautious yet optimistic stance is warranted, balancing the upside potential against the regulatory and earnings uncertainties.